EP Patent

EP3682007A2 — Galnac derivatives

Assigned to Janssen Biopharma Inc · Expires 2020-07-22 · 6y expired

What this patent protects

Modified oligonucleotides comprising a GalNAc moiety of the present disclosure along with methods of making and use, e.g., against HBV are disclosed.

USPTO Abstract

Modified oligonucleotides comprising a GalNAc moiety of the present disclosure along with methods of making and use, e.g., against HBV are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP3682007A2
Jurisdiction
EP
Classification
—
Expires
2020-07-22
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.